DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q3 2024 vs. Q2 2024
How the institutions holding DBV Technologies S.A. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 30 | 24 | −6 |
| Shares | 17.1M | 16.1M | −962.8K (−5.6%) |
| Value | $13.7M | $11.3M | −$2.39M (−17.5%) |
New holders (0)
Institutions that held DBV Technologies S.A. at the end of Q3 2024 but not at the end of Q2 2024.
None.
Sold out (6)
Institutions that held DBV Technologies S.A. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| UBS Group AG | 22,010 | $17.6K |
| HRT Financial LP | 22,338 | $17.0K |
| Landscape Capital Management, L.L.C. | 20,703 | $16.6K |
| Royal Bank of Canada | 5,305 | $4.00K |
| Triad Wealth Partners, LLC | 102 | $82 |
| Advisor Group Holdings, Inc. | 117 | $65 |